Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGS-v PLUS
- Development stage
- Phase 1
- Lead developer
- Imutex
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
AGS-v PLUS is a synthetic peptide vaccine designed to protect against multiple mosquito-borne diseases by targeting proteins found in mosquito saliva. It contains five synthetic peptides derived from the salivary glands of various mosquito species, including Aedes aegypti, Aedes albopictus, Anopheles gambiae, Anopheles darlingi, and Culex quinquefasciatus. The vaccine aims to induce an immune response that blocks the transmission of pathogens at the site of a mosquito bite by neutralizing key salivary proteins involved in facilitating infection. This approach could provide broad protection against diseases such as Zika virus infection, dengue fever, chikungunya fever, yellow fever, malaria, West Nile virus infection, and other arboviral diseases. Preclinical studies have shown that immunization with AGS-v PLUS can reduce viremia and morbidity associated with arboviral infections in animal models. Phase 1 clinical trials demonstrated that the vaccine is safe and elicits strong humoral (IgG) and cellular (IFN-γ) immune responses in healthy adults[1][4][5][6][7].
- Other names
- AGS-v PLUS vaccine with Montanide ISA-51 AdjuvantAGS-v PLUS/ISA-51
Beyond the preview
Go deeper on AGS-v PLUS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGS-v PLUS.